56
Headline
Updated AAN and AHS Guidelines Recommend Earlier Preventive Pharmacotherapy for Migraine, Supported by High-Confidence Evidence for CGRP Inhibitors and OnabotulinumtoxinA
1-Minute Summary
The American Academy of Neurology (AAN) and the American Headache Society (AHS) have released an updated clinical practice guideline in Neurology evaluating pharmacological prevention in adults with episodic and chronic migraine. Based on a comprehensive systematic review of 217 studies published through June 6, 2024, the multidisciplinary panel established high-confidence evidence supporting the efficacy of galcanezumab and erenumab for episodic migraine, as well as fremanezumab, galcanezumab, and onabotulinumtoxinA for chronic migraine, in significantly reducing monthly headache frequency compared with placebo. The updated recommendations advise clinicians to offer preventive therapy to patients experiencing 4 or more migraine days per month, 4 or more moderate-to-severe headache days per month, or migraine-related occupational and functional impairment. Emphasizing a substantial nationwide treatment gap, the authors provide tailored guidance across complex clinical contexts, including pregnancy, medication overuse, and medical comorbidities.
Why This Matters
Migraine remains among the leading causes of years lived with disability globally, yet preventive interventions remain substantially underutilized in clinical practice. The prior landmark AAN guideline on pharmacological prevention was published in 2012, prior to the clinical emergence and approval of disease-specific therapies targeting the calcitonin gene-related peptide (CGRP) pathway. By synthesizing over a decade of trial data alongside older conventional agents, this updated framework equips neurologists, primary care clinicians, and headache specialists with evidence-based criteria to initiate preventive therapies earlier and individualize drug selection based on patient-specific comorbidity profiles.
Study at a Glance
| Feature | Details |
| Study type | Systematic review and clinical practice guideline update |
| Participants | Adult patients ($\ge$18 years) with episodic or chronic migraine, including special patient populations (e.g., pregnancy, obesity, hypertension, fibromyalgia, and medication overuse) |
| Intervention | Preventive pharmacotherapies, including CGRP-targeted therapies (monoclonal antibodies), onabotulinumtoxinA, and established oral preventive agents |
| Comparator | Placebo or active comparative controls across 217 reviewed clinical trials |
| Primary outcome | Reduction in monthly headache/migraine frequency, functional disability, and adverse event/safety profiles |
| Main finding | High-confidence evidence confirms galcanezumab and erenumab reduce headache frequency in episodic migraine; fremanezumab, galcanezumab, and onabotulinumtoxinA demonstrate high-confidence efficacy in chronic migraine. Preventive therapy is recommended for $\ge$4 migraine days/month or substantial functional impairment. |
| Follow-up | Variable durations across 217 studies published up to June 6, 2024 |
What the Researchers Found
The guideline was formulated by a multidisciplinary panel convened in January 2018 comprising AAN and AHS content experts, methodologists, and patient advocates. The panel evaluated 217 clinical trials published through June 6, 2024, to assess efficacy, tolerability, and safety profiles across episodic and chronic migraine populations.
Co-author Rebecca C. Burch, MD, neurologist and headache specialist at the University of Vermont Medical Center, contextualized the update:
โSince the previous guidelines were published in 2012, there has been a wealth of new treatments available for prevention of migraine, and specifically the migraine-specific [calcitonin gene-related peptide] targeted therapy category. These guidelines include evidence for these newer treatments and also include information about older treatments that has been released in the past several years.โ
Evidence-Rated Preventive Options by Migraine Phenotype
| Migraine Classification | Preventive Agent | Mechanism of Action | Evidence Confidence | Primary Efficacy Endpoint |
| Episodic Migraine | Galcanezumab | Anti-CGRP ligand mAb | High Confidence | Superior to placebo in reducing monthly headache frequency |
| Erenumab | Anti-CGRP receptor mAb | High Confidence | Superior to placebo in reducing monthly headache frequency | |
| Chronic Migraine | Fremanezumab | Anti-CGRP ligand mAb | High Confidence | Superior to placebo in reducing monthly headache frequency |
| Galcanezumab | Anti-CGRP ligand mAb | High Confidence | Superior to placebo in reducing monthly headache frequency | |
| OnabotulinumtoxinA | Presynaptic acetylcholine release inhibitor | High Confidence | Superior to placebo in reducing monthly headache frequency |
Criteria for Initiating Preventive Therapy
| Clinical Indicator | Guideline Threshold / Recommendation |
| Headache Frequency | $\ge$4 migraine days per month |
| Severity Threshold | $\ge$4 moderate-to-severe headache days per month |
| Functional Impairment | Attacks substantially impairing ability to work, attend school, or manage daily activities |
| Comorbid Considerations | Individualize agent selection based on comorbidities (hypertension, obesity, fibromyalgia, medication overuse) |
Dr. Burch noted that a critical objective of the panel was clarifying clinical eligibility thresholds to overcome historical prescribing inertia:
โOne of the goals with this guideline was to be clear about who is eligible for prevention, and it really is more people than are receiving preventive treatment right now. My hope is that this guideline helps clinicians feel more comfortable prescribing preventive treatments for people with migraine.โ
Clinical Significance
A key finding highlighted by the authors is that a broad population of eligible patients in the United States does not receive evidence-based preventive treatment. By formalizing clear, symptom-day thresholds ($\ge$4 days per month) and incorporating functional disability as a standalone trigger for initiation, the guideline supports moving away from an exclusively acute, rescue-based treatment paradigm toward proactive disease modification.
Furthermore, integrating newer CGRP monoclonal antibodies alongside onabotulinumtoxinA provides clinicians with high-confidence biologics that feature favorable tolerability profiles, potentially mitigating the high discontinuation rates historically associated with legacy oral agents (e.g., topiramate, beta-blockers, and tricyclic antidepressants).
Limitations
- Synthesis of Diverse Trial Designs: The 217 reviewed clinical trials varied across study durations, primary outcome definitions, and background acute medication overuse allowances.
- Limited Evidence in Vulnerable Populations: High-confidence randomized controlled trial data remain limited for pregnant individuals, necessitating conservative, shared decision-making recommendations.
- Economic Constraints: Real-world prescription patterns remain influenced by medication costs, insurance prior authorization criteria, and step-therapy mandates, factors that exist outside clinical trial efficacy findings.
What Doctors Should Know
- Adopt Clear Thresholds for Prevention: Proactively offer preventive therapy to patients experiencing $\ge$4 migraine days per month, $\ge$4 moderate-to-severe headache days per month, or attacks that compromise workplace productivity and daily functioning.
- Select High-Confidence First-Line Agents:
- For episodic migraine, prioritize agents supported by high-confidence evidence, including galcanezumab and erenumab.
- For chronic migraine, consider fremanezumab, galcanezumab, or onabotulinumtoxinA.
-
- Manage Pregnancy and Conception Conservatively: Prioritize nonpharmacological strategies (e.g., biofeedback, sleep hygiene, trigger mitigation) for pregnant individuals or those actively planning pregnancy. Introduce pharmacological prophylaxis only after structured, transparent discussions regarding potential fetal risks versus maternal disease burden.
- Tailor to Comorbidities: Leverage comorbid conditions (e.g., co-existing hypertension, obesity, fibromyalgia, or medication overuse headache) to guide drug selection and optimize therapeutic synergy.
Bottom Line
The updated AAN/AHS clinical practice guideline establishes high-confidence evidence for CGRP-targeted monoclonal antibodies and onabotulinumtoxinA in reducing migraine frequency, recommending that clinicians initiate preventive treatment in patients with 4 or more migraine days per month or migraine-related functional impairment.
Original Research / DOI
Potrebic S, et al. Neurology. 2026.
